[1] Zheng JP, Miao HX, Zheng SW, et al. Risk factors for osteoporosis in liver cirrhosis patients measured by transient elastography. Medicine (Baltimore). 2018;97(20):e10645. [2] Hayashi M, Abe K, Fujita M, et al. Association between sarcopenia and osteoporosis in chronic liver disease. Hepatol Res. 2018. doi: 10. 1111/hepr. 13192. [3] Nakchbandi IA, Swv DM. Current understanding of osteoporosis associated with liver disease. Nat Rev Gastroenterol Hepatol. 2009;6(11):660-670.[4] Li F, He ZG, Tu GQ, et al. Effect of heat-sensitive point moxibustion on BMD, S-AKP, U-Ca/Cr in patients with primary osteoporosis. Zhongguo Zhen Jiu. 2011;31(3):223-226. [5] 周百岁,崔晓纯,李传波.鲑鱼降钙素对病毒性肝硬化合并骨质疏松症患者影响的临床研究[J].中国骨质疏松杂志,2018,24(2): 226-229.[6] Kovacs CS. Calcium, phosphorus, and bone metabolism in the fetus and newborn. Early Hum Dev. 2015;91(11):623-628. [7] Zheng XK, Zhang X, Wang XL, et al. Effect of estrogen-like effective part of Selaginella tarmariscina on bone metabolism in ovariectomized rats. Zhong Yao Cai. 2014;37(10): 1825-1829. [8] Galiatina TA, Ust'iantseva IM, Khokhlova OI. The characteristics of regulation of bone remodeling under inherent pathology of locomotive system in children. Klin Lab Diagn. 2014;(4):17-21. [9] Liu P, Yang DQ, Xie F, et al. Effect of calcitonin on anastrozole-induced bone pain during aromatase inhibitor therapy for breast cancer. Genet Mol Res. 2014;13(3): 5285-5291. [10] Dexue L, Yueyue Z. Salmon calcitonin in the treatment of elderly women with type 2 diabetes complicated with osteoporosis. Pak J Pharm Sci. 2014;27(6 Suppl):2079-2081[11] Atbinici H, Sipahio?lu S, Aksoy N, et al. Effects of salmon calcitonin treatment on serum and synovial fluid bone formation and resorption markers in osteoporosis patients. Acta Orthop Traumatol Turc. 2015;49(2):160-165. [12] Henriksen K, Byrjalsen I, Andersen JR, et al. A randomized, double-blind, multicenter, placebo-controlled study to evaluate the efficacy and safety of oral salmon calcitonin in the treatment of osteoporosis in postmenopausal women taking calcium and vitamin D. Bone. 2016;91:122-129. [13] Kanis JA. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporos Int. 1994;4(6): 368-381. [14] 中华医学会传染病与寄生虫病学分会、肝脏病学分会.病毒性肝炎防治方案[J].中华传染病杂志,2001,19(1):566.[15] Harding AT, Weeks BK, Watson SL, et al. The LIFTMOR-M (Lifting Intervention For Training Muscle and Osteoporosis Rehabilitation for Men) trial: protocol for a semirandomised controlled trial of supervised targeted exercise to reduce risk of osteoporotic fracture in older men with low bone mass. BMJ Open. 2017;7(6):e014951. [16] Klotz LH, McNeill IY, Kebabdjian M, et al. A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) study. Eur Urol. 2013;63(5):927-935. [17] You L, Sheng ZY, Chen JY, et al. The safety and efficacy of early-stage bi-weekly alendronate to improve bone mineral density and bone turnover in chinese post-menopausal women at risk of osteoporosis. J Int Med Res. 2011;39(1): 302-310. [18] Pountos I, Panteli M, Lampopoulos A, et al. The role of peptides in bone healing and regeneration: a systematic review. BMC Med. 2016;14(1):1-15. [19] Hay JE, Malinchoc M, Dickson ER. A controlled trial of calcitonin therapy for the prevention of post-liver transplantation atraumatic fractures in patients with primary biliary cirrhosis and primary sclerosing cholangitis. J Hepatol. 2001;34(2):292-298. [20] Camisasca M, Crosignani A, Battezzati PM, et al. Parenteral calcitonin for metabolic bone disease associated with primary biliary cirrhosis. Hepatology. 1994;20(3):633-637. |